APOE gene polymorphisms and susceptibility to Creutzfeldt–Jakob disease

Wei, Yunfei; Tang, Yanyan; He, Wenwu; Qu, Zhanli; Zeng, Jinming; Qin, Chao

doi:10.1016/j.jocn.2013.07.019

Cited by 16 publications

(11 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results are, however, keeping with previous studies. In meta-analysis an association between the ε4 allele and CJD has been shown [46], and synergistic effects between APOE ε4 and the PRNP gene, the most prominent risk factor of CJD, has been suggested in both AD and CJD [47].…”

Section: Discussionmentioning

confidence: 99%

Apolipoprotein E genotypes and longevity across dementia disorders

Skillbäck

Lautner

Mattsson

et al. 2018

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Apolipoprotein E genotypes and longevity across dementia disorders

Skillbäck

Lautner

Mattsson

et al. 2018

Alzheimer's & Dementia

View full text Add to dashboard Cite

show abstract

“…Recent meta analyses suggest that ApoE4 carriers might be more susceptible to Creutzfeldt–Jakob disease (Wei et al, 2014). ApoE2 in turn might increase the risk of age-related macular degeneration (Leduc et al, 2011) and Parkinson disease (Huang et al, 2004) highlighting again the ambiguous role of ApoE2.…”

Section: Risk Assessmentmentioning

confidence: 99%

“…Creutzfeldt-Jakob disease, gallbladder stone disease, Huntington's disease, inclusion-body myositis, cerebral palsy, progressive supranuclear palsy, temporal lobe epilepsy multiple system atrophy, multiple sclerosis, frontotemporal dementia, malaria and herpes simplex virus need further exploration (Bu, 2009; Leduc et al, 2011; Verghese et al, 2011; Xue et al, 2012; Yin et al, 2012; Rubino et al, 2013; Wei et al, 2014). …”

Section: Risk Assessmentmentioning

confidence: 99%

The potential applications of Apolipoprotein E in personalized medicine

Villeneuve

Brisson

Marchant

et al. 2014

Front. Aging Neurosci.

View full text Add to dashboard Cite

Personalized medicine uses various individual characteristics to guide medical decisions. Apolipoprotein (ApoE), the most studied polymorphism in humans, has been associated with several diseases. The purpose of this review is to elucidate the potential role of ApoE polymorphisms in personalized medicine, with a specific focus on neurodegenerative diseases, by giving an overview of its influence on disease risk assessment, diagnosis, prognosis, and therapy. This review is not a systematic inventory of the literature, but rather a summary and discussion of novel, influential and promising works in the field of ApoE research that could be valuable for personalized medicine. Empirical evidence suggests that ApoE genotype informs pre-symptomatic risk for a wide variety of diseases, is valuable for the diagnosis of type III dysbetalipoproteinemia, increases risk of dementia in neurodegenerative diseases, and is associated with a poor prognosis following acute brain damage. ApoE status appears to influence the efficacy of certain drugs, outcome of clinical trials, and might also give insight into disease prevention. Assessing ApoE genotype might therefore help to guide medical decisions in clinical practice.

show abstract

“…And cholesterol played a protective role against prion protein-mediated neurotoxicity and oxidative stress [11]. A genetic association between ApoE polymorphisms and CJD has been verified [12].…”

Section: Discussionmentioning

confidence: 97%